APA (7th ed.) Citation

Wang, L., Mehrabi, A., Schubert, M., Schmitt, A., Neuber, B., Kunz, A., . . . Daniel, V. (2022). Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): Protocol for a multicentre, open-label, phase II, randomised controlled trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Lei, et al. Individualised Immunosuppression with Intravenously Administered Donor-derived Modified Immune Cells Compared with Standard of Care in Living Donor Kidney Transplantation (TOL-2 Study): Protocol for a Multicentre, Open-label, Phase II, Randomised Controlled Trial. BMJ Publishing Group, 2022.

MLA (9th ed.) Citation

Wang, Lei, et al. Individualised Immunosuppression with Intravenously Administered Donor-derived Modified Immune Cells Compared with Standard of Care in Living Donor Kidney Transplantation (TOL-2 Study): Protocol for a Multicentre, Open-label, Phase II, Randomised Controlled Trial. BMJ Publishing Group, 2022.